CoChat

Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis

Open access
Wang, Xiaohui, Bao, Zhengqiang, Zhang, Xiaoju, Li, Fei, Lai, Tianwen, Cao, Chao, Chen, Zhihua, Li, Wen, Shen, Huahao, Ying, Songmin · 2017 · Oncotarget
Cited by 75

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

// Xiaohui Wang 1,2,* , Zhengqiang Bao 1,2,* , Xiaoju Zhang 3,* , Fei Li 1 , Tianwen Lai 1 , Chao Cao 1 , Zhihua Chen 1 , Wen Li 1 , Huahao Shen 1,4 and Songmin Ying 1,2 1 Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Institute of Respiratory Diseases, Zhejiang University School of Medicine, Hangzhou, China 2 Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, China 3 Department of Respiratory Medicine, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China 4 State Key Laboratory of Respiratory Diseases, Guangzhou, China * These authors have contributed equally to this manuscript Correspondence to: Songmin Ying, email: // Huahao Shen, email: // Keywords : PD-1, PD-L1, nivolumab, pembrolizumab, cancer Received : August 12, 2016 Accepted : March 01, 2017 Published : May 31, 2017 Abstract Background: PD-1/PD-L1 inhibitors have been implicated as potentially effective anti-cancer therapies. Some clinical randomized controlled trials (RCTs) have been completed for a variety of PD-1/PD-L1 inhibitors to treat various malignancies, and more RCTs are still under way. We carried out this systematic meta-analysis to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors. Methods: We searched PubMed, EMBASE, clinical trial registers, conference reports, and related reviews. Eligible RCTs that compared PD-1/PD-L1 inhibitors with other chemotherapy agents or placebo in solid tumor patients were included. For each RCT, progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), stable disease rate (SDR), progressive disease rate (PDR), and adverse events (AEs) were pooled for meta-analysis. Findings: Based on an analysis of 10 eligible RCTs, PD-1/PD-L1 inhibitors were found to significantly improve PFS (Hazard ratio (HR), 0.65; 95% confidence interval (CI) 0.53 to 0.79, P <0.001), OS (HR, 0.69; 95%CI 0.62 to 0.76, P <0.001), and ORR (Risk Ratio (RR) 2 . 92; 95% confidence interval (CI) 2.06 to 4.15, P <0.00001) in all populations, including melanoma and NSCLC subgroups. However, they failed to increase the DCR of cancer patients (RR 1.15; 95%CI 0.91 to 1.45, P =0.25). Furthermore, less AEs were observed in the PD-1/PD-L1 inhibitor groups than the control groups. Interpretation: PD-1 inhibitors are more effective for improving the PFS, OS, and ORR of cancer patients with little toxicity, despite having little effect on increasing of the DCR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.18316

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

Metadata

Authors
Wang, X., Bao, Z., Zhang, X., Li, F., Lai, T., Cao, C., Chen, Z., Li, W., Shen, H., & Ying, S.
Venue
Oncotarget
Published
2017-05-31
Volume
8
Issue
35
Pages
59901-59914
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2619738298
Cited by
75
References
5
FWCI
1.27
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.